Table 1.
Baseline characteristics
| All, n (%) | Preexisting ILD | p | ||
|---|---|---|---|---|
| Yes, n (%) | No, n (%) | |||
| Patients | 331 | 17 | 314 | |
| Age | ||||
| Median (range) | 62 (30–84) | 66 (33–83) | 62 (30–84) | |
| ≥ 75 years | 38 (11) | 7 (41) | 31 (10) | 0.001 |
| Sex | 0.006 | |||
| Male | 216 (65) | 16 (94) | 200 (64) | |
| ECOG PS | 0.15 | |||
| 0–1 | 289 (87) | 13 (76) | 276 (88) | |
| ≥ 2 | 42 (13) | 4 (24) | 38 (12) | |
| Smoking status | 0.084 | |||
| Never-smoker | 74 (23) | 1 (6) | 73 (24) | |
| Current or former smoker | 249 (77) | 15 (94) | 234 (76) | |
| Histology | 0.012 | |||
| Squamous | 69 (21) | 8 (47) | 61 (19) | |
| Nonsquamous | 262 (79) | 9 (53) | 253 (81) | |
| Clinical stage | 0.34 | |||
| III/IV | 248 (75) | 14 (82) | 234 (75) | |
| Recurrence | 83 (25) | 3 (18) | 80 (25) | |
| EGFR mutated | 57 (23) | 1 (11) | 56 (23) | 0.35 |
| PD-L1 22C3 TPS subgroups | 0.61 | |||
| < 1% | 48 (23) | 3 (23) | 45 (23) | |
| ≥ 1% | 161 (77) | 10 (77) | 151 (77) | |
| Prior curable operation | 76 (23) | 3 (18) | 73 (23) | 0.42 |
| Thoracic radiotherapy | 125 (38) | 5 (29) | 120 (38) | 0.32 |
| Treatment line | 0.046 | |||
| 1 | 41 (12) | 5 (29) | 36 (11) | |
| 2– | 290 (83) | 12 (71) | 278 (89) | |
| Drug | 0.43 | |||
| Nivolumab | 248 (75) | 12 (71) | 236 (75) | |
| Pembrolizumab | 83 (25) | 5 (29) | 78 (25) | |
ILD, interstitial lung disease; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; PD-L1, programmed death ligand 1; TPS, tumor proportion score